Evaluation of procalcitonin with liquid-phase binding assay in hematological malignancy.

Related Articles

Evaluation of procalcitonin with liquid-phase binding assay in hematological malignancy.

Clin Chim Acta. 2012 Oct 9;413(19-20):1633-6

Authors: Koya J, Nannya Y, Kurokawa M

Abstract
BACKGROUND: To determine procalcitonin (PCT) levels in blood, a newly analyzer based on liquid-phase binding assay (LBA) was developed (micro-total analysis system, μTAS). We evaluated analytical and clinical performance of this system in comparison with autoanalyzer based on chemiluminescence enzyme immunoassay (CLEIA), which is widely-used but takes much longer time than LBA.
METHODS: A total of 518 serum samples from 28 patients undergoing hematopoietic stem cell transplantation were analyzed. The correlation between the 2 methods and the comparison of the each area under the receiver operating characteristics curve (AUC) for distinguishing bacterial or fungal infections from other events were evaluated.
RESULTS: The minimum detection limit of serum PCT levels by LBA was 0.02 ng/ml. There was an excellent correlation between the two methods in all samples (r²=0.99), the samples obtained on days of fever onset (r²=0.99), and the samples collected in neutropenic state (r²=0.99). The AUC for detection of bacterial or fungal infection on the onset of fever was not significantly different between LBA and CLEIA (0.80 by LBA and 0.82 by CLEIA, P=0.19).
CONCLUSIONS: The PCT measurement using LBA was well correlated with conventional method based on CLEIA and had enough clinical performance to detect bacterial or fungal infection in clinical setting.

PMID: 22579768 [PubMed - indexed for MEDLINE]